• Study Resource
  • Explore Categories
    • Arts & Humanities
    • Business
    • Engineering & Technology
    • Foreign Language
    • History
    • Math
    • Science
    • Social Science

    Top subcategories

    • Advanced Math
    • Algebra
    • Basic Math
    • Calculus
    • Geometry
    • Linear Algebra
    • Pre-Algebra
    • Pre-Calculus
    • Statistics And Probability
    • Trigonometry
    • other →

    Top subcategories

    • Astronomy
    • Astrophysics
    • Biology
    • Chemistry
    • Earth Science
    • Environmental Science
    • Health Science
    • Physics
    • other →

    Top subcategories

    • Anthropology
    • Law
    • Political Science
    • Psychology
    • Sociology
    • other →

    Top subcategories

    • Accounting
    • Economics
    • Finance
    • Management
    • other →

    Top subcategories

    • Aerospace Engineering
    • Bioengineering
    • Chemical Engineering
    • Civil Engineering
    • Computer Science
    • Electrical Engineering
    • Industrial Engineering
    • Mechanical Engineering
    • Web Design
    • other →

    Top subcategories

    • Architecture
    • Communications
    • English
    • Gender Studies
    • Music
    • Performing Arts
    • Philosophy
    • Religious Studies
    • Writing
    • other →

    Top subcategories

    • Ancient History
    • European History
    • US History
    • World History
    • other →

    Top subcategories

    • Croatian
    • Czech
    • Finnish
    • Greek
    • Hindi
    • Japanese
    • Korean
    • Persian
    • Swedish
    • Turkish
    • other →
 
Profile Documents Logout
Upload
DMSO: Many Uses, Much Controversy
DMSO: Many Uses, Much Controversy

... In the first flush of enthusiasm over the drug, six pharmaceutical companies embarked on clinical studies. Then, in November 1965, a woman in Ireland died of an allergic reaction after taking DMSO and several other drugs. Although the precise cause of the woman’s death was never determined, the pres ...
AGNP Consensus Guidelines for Therapeutic Drug Monitoring in
AGNP Consensus Guidelines for Therapeutic Drug Monitoring in

... The benefits of TDM regarding the optimization of pharmacotherapy, however, can only be obtained if the method is adequately integrated into the clinical treatment process. Current TDM use in psychiatric care is obviously suboptimal [134, 700, 742]. Similar to other medical disciplines, systematic s ...
Pharmaceutical Administration and Regulations in Japan
Pharmaceutical Administration and Regulations in Japan

... January 6, 2001 as part of the government program for reorganizing government ministries. The MHLW, which was originally established in 1938, has been in charge of the improvement and promotion of social welfare, social security and ...
navigating the fda
navigating the fda

... Range: 2 – 10 years (average 5 – 7 years) • Phase 1 1 + years • Phase 2 2 + years • Phase 3 3 + years NDA usually 100,000 pages in length, takes at least 6 months to review. Average 2 years (range 2 months to 7 years.) NAVIGATING THE FDA ...
The FDA’s Continuing Incapacity on Livestock Antibiotics *
The FDA’s Continuing Incapacity on Livestock Antibiotics *

... explain here, however, the initiatives leave much to be desired, for four basic reasons. First, the success of the FDA’s policy on “judicious use” depends on multiple layers of voluntary action by profit-maximizing drug companies. Although early indications of drug companies’ cooperation are promisi ...
The incentive sensitization theory of addiction
The incentive sensitization theory of addiction

... the expression of such non-associative motivation processes as stress and pain. The contextual control over the expression of sensitization provides an additional mechanism that accounts for why addicts ‘want’ drugs most particularly when they are in drugassociated contexts. Finally, by spreading be ...
NC Division of Medical Assistance Medicaid and Health Choice
NC Division of Medical Assistance Medicaid and Health Choice

... Online Point-of-Sale Processing Downtime ..................................................................... 30 Compound Prescription Claims on Point-of-Sale ............................................................. 31 Point-of-Sale Claims over $9,999 .......................................... ...
Abuse Liability & Drug Scheduling: Role of FDA
Abuse Liability & Drug Scheduling: Role of FDA

... Paths to ibogaine availability 1. Pharmaceutical company or government agency prepared to finance regulatory development. 2. Supplies of pharmaceutical grade ibogaine. 3. Grassroots constituency demanding availability of ibogaine. 4. Political advocacy movement to pressure government and industry i ...
FDA Enforcement of Criminal Liability for Clinical
FDA Enforcement of Criminal Liability for Clinical

... generally Pamela H. Bucy, Symposium: The Path From Regulator to Hunter: The Exercise of Prosecutorial Discretion in the Investigation of Physicians at Teaching Hospitals, 44 ST. LOUIS L.J. 3 (2000). For a discussion of civil liability for committing investigator fraud, see generally E. Haavi Morreim ...
Best Drugs for Avoiding Paradoxical Bronchospasm
Best Drugs for Avoiding Paradoxical Bronchospasm

... showed lower variability than resistance of airways and changes more significantly than FVC and MMEF (9). According to previous reports on levalbuterol and ipratropium, before the study we expected that these drugs induce higher degree of bronchodilation and lesser frequency of paradoxical bronchosp ...


... Take this medication with a full glass of water. Effexor should be taken with food. Try to take Effexor at the same time each day. Swallow the controlled-release capsule (Effexor XR) whole, without crushing or chewing. To make the medication easier to swallow, you may open the Effexor XR capsule and ...
Macromolecules in drug delivery
Macromolecules in drug delivery

... SECTION 3 – Macromolecular drugs Therapeutic proteins are examples of carriers which are simultaneously drugs  Proteins that are engineered in the laboratory for pharmaceutical use are known as therapeutic proteins.  The majority of biopharmaceuticals marketed to date are recombinant therapeutic ...
Complaint Filed in US District Court, Midland
Complaint Filed in US District Court, Midland

... part of the delivery of health care in the United States for both human and animal health. ...
A SURVEY BASED STUDY IN CURRENT SCENARIO OF GENERIC AND... Research Article
A SURVEY BASED STUDY IN CURRENT SCENARIO OF GENERIC AND... Research Article

... (science background), Common public (educated but non science background) and Practicing Pharmacists. The different sets of questionnaire were prepared for each group and survey was conducted. The questions were designed as to check awareness, knowledge and preference of medication. Results: The hig ...
27 Gastrointestinal drugs
27 Gastrointestinal drugs

... active than the parent molecule. Any antibacterial that reduces intestinal flora may therefore reduce the formation of this metabolite. However, the manufacturer notes that as this metabolite is not required for efficacy, no alvimopan dose adjustment is needed if antibacterials are also given.2 ...
Aspects to consider when using a syringe driver in the community
Aspects to consider when using a syringe driver in the community

... The responsibility for their use lies with the prescriber. Diamorphine, Hyoscine Hydrobromide and Levomepromazine are the only drugs licensed for subcutaneous administration. However ‘licensed’ means a license for marketing. It is now accepted in the UK that it is acceptable to use unlicensed routes ...
of Pharmacy and Pharmacology African Journal
of Pharmacy and Pharmacology African Journal

... The most important pathway of metals to transport into human is from soil to plant and from plant to human. The levels of the mineral essential elements (Ca, Mg, Na, K and Fe) detected in the investigated herbal drugs are presented as mg/kg in Table 2. The data revealed that all analyzed elements we ...
et al. Madhu E. Nicholas* , Shanker Panaganti , L. Prabakaran
et al. Madhu E. Nicholas* , Shanker Panaganti , L. Prabakaran

... highly populated with bacteria and other microflora at both ends, the oral cavity and the colon/rectum. In between these two sites, the GIT is very sparsely populated with microorganisms. Microorganisms of the oral cavity do not normally affect oral drug delivery systems and as such will not be cons ...
Impact of Ignoring Extraction Ratio When Predicting Drug
Impact of Ignoring Extraction Ratio When Predicting Drug

... moderate to high EH drugs, either predictions have been made with the assumption that the drug is a low EH drug (Ito et al., 1998; Ernest et al., 2005; Fahmi et al., 2008; Shou et al., 2008) or a ratio of the full well stirred model has been used, necessitating an estimate of the true hepatic intrin ...


... the target site concentration directly linked to therapeutic drug effect as a means of optimizing individualized drug therapy 20. Most new chemical entities often fail during drug development processes because of an inadequate ...
Choose the Only FDA-approved Hyaluronidase
Choose the Only FDA-approved Hyaluronidase

... larger amounts of hyaluronidase for equivalent dispersing effect, since these drugs apparently render tissues partly resistant to the action of hyaluronidase. Edema has been reported most frequently in association with subcutaneous fluid administration. The rate and volume of subcutaneous fluid admi ...
Drug effects on salivary glands: dry mouth
Drug effects on salivary glands: dry mouth

... antidepressants or anti-asthma drugs (Thomson et al, 2000). It is clear that medication is a better predictor of risk status for dry mouth, than either age or gender (Field et al, 2001). Even in elderly patients with advanced cancer, dry mouth was the fourth most common symptom (78% of patients), bu ...
Safe Handling of Hazardous Drugs
Safe Handling of Hazardous Drugs

... experimental animals or treated patients. The National Institute of Occupational Safety and Health (NIOSH) revised the definition in 2004 to include drugs that exhibit one or more of the following six characteristics in humans or animals: carcinogenicity, teratogenicity or other developmental toxici ...
DME Drugs And Supplies - National Government Services
DME Drugs And Supplies - National Government Services

... reasonable effort has been made to assure the accuracy of the information within these pages at the time of publication, the Medicare Program is constantly changing, and it is the responsibility of each provider to remain abreast of the Medicare Program requirements. Any regulations, policies and/or ...
Foundation - The Learning Oasis
Foundation - The Learning Oasis

... the relationship between cowpox and smallpox. Each major capital city in Europe published a list of commonly used drugs. The most notable of these is the one created in Great Britain, Martindale’s Pharmacopoeia. It was also during this time that pharmacists began to be recognized as healthcare provi ...
< 1 ... 3 4 5 6 7 8 9 10 11 ... 161 >

Orphan drug

An orphan drug is a pharmaceutical agent that has been developed specifically to treat a rare medical condition, the condition itself being referred to as an orphan disease.In the US and EU it is easier to gain marketing approval for an orphan drug, and there may be other financial incentives, such as extended exclusivity periods, all intended to encourage the development of drugs which might otherwise lack a sufficient profit motive. The assignment of orphan status to a disease and to any drugs developed to treat it is a matter of public policy in many countries, and has resulted in medical breakthroughs that may not have otherwise been achieved due to the economics of drug research and development.According to Thomson Reuters in their 2012 publication ""The Economic Power of Orphan Drugs"", there has been increased investing in orphan drug Research and Development partly due to the U. S. Orphan Drug Act (ODA) 1983 and similar Acts in other regions of the world and also driven by ""high-profile philanthropic funding."" The period between 2001 to 2011 was the ""most productive period in the history of orphan drug development, in terms of average annual orphan drug designations and orphan drug approvals."" For the same decade the compound annual growth rate (CAGR) of the orphan drugs was an ""impressive 25.8 percent, compared to only 20.1 percent for a matched control group of non-orphan drugs."" By 2012 the market for orphan drugs was worth USD$637 million compared to the USD$638 million matched control group of non-orphan drugs, Thomson Reuters.By 2012, ""the revenue-generating potential of orphan drugs [was] as great as for non-orphan drugs, even though patient populations for rare diseases are significantly smaller. Moreover, we suggest that orphan drugs have greater profitability when considered in the full context of developmental drivers including government financial incentives, smaller clinical trial sizes, shorter clinical trial times and higher rates of regulatory success.""
  • studyres.com © 2025
  • DMCA
  • Privacy
  • Terms
  • Report